Select your languague:
Buy Proscar (Finasteride 5mg) online from EU registered pharmacies


What is Proscar?

Proscar will drop the production of testosterone in your body through its active ingredient, finasteride. Since testosterone stimulates the prostate to grow, this medicine can be vital to stop that process. Proscar targets the urinary issues created by the enlargement of the prostate. This condition, benign prostatic hyperplasia, or BPH may include symptoms like: you need to urinate all the time (but mostly at night), an interrupted and weak urinary stream and involuntary discharge of urine. Since prostate and urinary problems are common in older men, Proscar is the perfect solution to deal with this.

Price of Proscar and where to buy:
       Treatment Dosage Quantity Per Pill Price Buy now
Proscar Proscar 5mg 30 £2.86 £85.70 Buy Now

*Prices are subject to change due to fluctuations and may differ from the price shown for the item on the product detail page. Items in your shopping cart will always reflect the recent and final price.

Buy Proscar With an Online Prescription

An online doctor consultation means filling out a medical questionnaire. A registered EU doctor assesses your medical questionnaire and analize whether Proscar (finasteride 5mg) is suitable and safe for you to buy. After approval, a prescription is issued and send to the registered EU pharmacy. You will receive your discretely shipped Proscar pills within 3 business days.


Finasteride is a specific inhibitor of type II 5-alpha reductase, an intracellular enzyme that converts testosterone to the more active androgen, dihydrotestosterone (DHT). With BPH, its increase depends on the conversion of testosterone to DHT in the tissues of the prostate. Finasteride highly reduces both circulating and intra-prostatic DHT. Finasteride is not related to androgen receptors. In clinical trials involving patients with moderate to severe manifestations of BPH, an enlarged prostate during digital rectal examination, and a low residual urine volume, Proscar reduced the frequency of acute urinary retention from 7/100 to 3/100 in four years and the need for surgery ( transurethroresection of the prostate and prostatectomy) from 10/100 to 5/100. This decrease was accompanied by a 2-point improvement on the QUASI-AUA symptom score scale (range 0-34), significant regression of prostate volume by about 20%, and a significant increase in urine flow rate. The MTOPS (Medical Treatment for Prostatic Symptoms) study was a 4–6 year study involving 3047 men with symptomatic BPH who were randomized to finasteride, 5 mg / day, doxazosin, 4 or 8 mg / day, finasteride combinations, 5 mg / day, and doxazosin, 4 or 8 mg / day, or placebo. The primary follow-up point was the time until the clinical progression of BPH (defined as an increase of 4 or more points on the symptom score from the beginning, an episode of acute urinary retention associated with BPH, renal failure, recurrence of urinary tract infection or urosepsis, or urinary incontinence). Compared with placebo, treatment with finasteride, doxazosin or a combination significantly reduced the risk of clinical progression of BPH by 34%, respectively (p = 0.002), 39% (p


In men, after a single dose of finasteride labeled with carbon isotopes 14 C, 39% of the dose taken was excreted in the urine in the form of metabolites (presumably, a small amount of unchanged finasteride was also excreted in the urine). 57% of the dose taken was excreted in the feces. Studies have also found that the two metabolites of finasteride tend to have a less pronounced inhibitory effect on 5-alpha reductase. The oral bioavailability of finasteride is approximately 80%. Eating does not affect the bioavailability of the drug. The maximum concentration of finasteride in blood plasma is reached 2:00 after oral administration. The absorption of the drug from the gastrointestinal tract ends 6-8 hours after administration. The half-life of finasteride in blood plasma is on average 6:00. Linking blood plasma proteins - 93%. The systemic clearance is approximately 165 ml/min, the distribution volume is 76,

In old age, the rate of excretion of finasteride is somewhat reduced. In men older than 70 years, the half-life of finasteride is approximately 8:00, while in individuals aged 18 to 60 years - 6:00. But this is not an indication for discontinuing the drug in older people.

In patients with chronic renal failure (creatinine clearance from 9 to 55 ml/min), there was no difference in the rate of excretion of a single dose of finasteride labeled with carbon isotopes 14 C, compared with healthy volunteers. The binding to plasma proteins in these groups of patients also did not differ. This is due to the fact that in patients with renal failure, the percentage of finasteride metabolites, which under normal conditions is excreted in the urine, is excreted in the feces. This is confirmed by an increase in the number of metabolites of finasteride in feces in these patients while reducing their concentration in the urine. In connection with the given in patients with renal failure who are not shown hemodialysis, dose adjustment Proscar is not needed.

There are no data on the pharmacokinetics of the drug in patients with liver failure.

Finasteride crosses the blood-brain barrier. A small amount of finasteride was shown in seminal fluid.


Treatment and control of benign prostatic hyperplasia (BPH) in patients with an enlarged prostate gland in order to:

  • reduction in size (regression) of the enlarged gland, improvement of urine outflow and reduction of symptoms associated with BPH;
  • Reducing the risk of acute urinary retention and the need for surgical intervention, including transurethral resection of the prostate gland and prostatectomy.


Hypersensitivity to finasteride or to any component of this drug. Proscar is not indicated for use by women and children.

Pregnancy: use for women when they are or may be potentially pregnant (see section "Use during pregnancy or lactation").


The recommended dose is 1 tablet of 5 mg once a day during or regardless of food intake. Proscar a can be used as monotherapy in combination with the alpha-blocker doxazosin (see section "Pharmacological properties").

The duration of treatment is determined by the doctor individually. Despite the fact that improvement in symptoms can be observed earlier, at least a six-month intake of the drug is necessary to evaluate the effectiveness of the action, after which it is necessary to continue treatment.

For elderly patients and for patients with renal failure of varying severity (decrease in creatinine clearance to 9 ml/min) dose adjustment is not required.

There is no data on the use of the drug in patients with impaired liver function. Do not use in children.


Women who may become pregnant or pregnant should avoid contact with crushed Proscar® tablets or those who have lost their integrity.

Available data on the release of a small amount of finasteride from the patient's sperm took finasteride 5 mg/day. It is not known whether the male fetus can be adversely affected by the fact that the patient’s sperm influenced his mother and was treated with finasteride. If the patient’s sexual partner or is potentially pregnant, the patient is advised to avoid exposure to sperm on the partner.

Due to the ability of type II 5-alpha reductase inhibitors to inhibit the conversion of testosterone to dihydrotestosterone, these drugs, including finasteride, can cause disturbances in the development of the external genital organs of the male fetus. 

Proscar's tablets are coated and this prevents contact with the active ingredient, provided that the tablets are not crushed and have not lost their integrity.

  • Use during lactation.
  • Proscar is not shown to women. Unknown, finasteride penetrates into mother's milk.
  • Proscar is contraindicated in children.
  • Safety and effectiveness for the use of the drug in children have not been established.
  • general events

It is necessary to carefully monitor the possible development of obstructive uropathy in patients with a large residual urine volume and/or sharply reduced urine flow.

The clinical benefits of Proscaroma treatment in patients with prostate cancer have not yet been shown. Patients with prostate adenoma and elevated PSA levels were observed in controlled clinical trials with several definitions of PSA and a prostate biopsy. In these studies, Proscaroma treatment did not affect the incidence of prostate cancer. The overall incidence of prostate cancer did not differ significantly in the groups of patients who received Proscar or placebo.

Before starting treatment and periodically during treatment with Proscar, it is recommended that patients be examined by rectal examination and other methods for the presence of prostate cancer. Serum PSA determination is also used to detect prostate cancer. In general, with a baseline PSA level of more than 10 ng/ml (Hybritech), a thorough examination of the patient should be carried out, including, if necessary, a biopsy. With a PSA level in the range of 4-10 ng/ml, further examination of the patient is recommended. There is a significant overlap in PSA levels in men with prostate cancer who do not have this disease. So, in men with prostate adenoma, normal PSA values ​​do not rule out prostate cancer, regardless of Proscar's treatment.

Proscarva causes a decrease in serum PSA by approximately 50% in patients with prostate adenoma, even in the presence of prostate cancer. This decrease in serum PSA levels in patients with prostate adenoma receiving Proscaroma treatment should be taken into account when evaluating PSA levels since this decrease does not exclude concomitant prostate cancer. This decrease is predictable over the entire range of PSA levels, although this may vary in individual patients. In most patients who receive Proscar® for 6 months or more, PSA values ​​should be doubled compared to normal values ​​for those not taking treatment. Such a correction allows preserving the sensitivity and specificity of PSA determination and supports its ability to detect prostate cancer.

With any prolonged increase in PSA levels in a patient receiving treatment with finasteride 5 mg, a thorough examination is necessary to determine the causes, including non-compliance with Proscar's regimen.

 Influence on laboratory data. Effect on PSA Level

Serum PSA levels correlate with the patient’s age and prostate volume, while the prostate volume correlates with the patient’s age. When evaluating PSA laboratory parameters, it is necessary to take into account the fact that the PSA level decreases during the treatment with Proscar. Most patients experience a rapid decrease in PSA during the first months of treatment, after which the PSA level stabilizes at a new level, which is approximately half the baseline value. From this point of view, in typical patients receiving Proscar for 6 months or more, PSA values ​​should be doubled compared to normal values ​​in people not taking treatment.


The most common side effects are impotence and decreased libido. These adverse reactions occur at the beginning of the course of therapy and pass with further treatment in most patients.

Adverse reactions reported during clinical trials and/or during post-marketing use are listed in the table below.

The frequency of adverse reactions is defined as: very often (≥1 / 10), often (≥1 / 100 - <1>

organ system
frequency of manifestations
From the immune system
Unknown:  hypersensitivity reactions, including pruritus, urticaria and Quincke edema (including swelling of the lips, tongue, throat, and face)
From the psyche
Often a  decrease in libido.
Unknown:  decreased libido, which may continue after discontinuation of therapy, depression.
From the cardiovascular system
Unknown:  palpitations.
On the part of the liver and biliary tract
Unknown:  elevated levels of liver enzymes.
On the part of the skin and subcutaneous tissue
Infrequently rash.
Unknown:  pruritus, urticaria.
From the reproductive system and mammary glands
Often impotence.
Infrequent ejaculation disorder, soreness, and enlargement of the mammary glands.
Unknown:  pain in the testicles, erectile dysfunction, which may last after discontinuation of treatment; male infertility and/or reversible impairment of sperm quality (normalization or improvement of sperm quality was reported after stopping the use of finasteride).
by research
Often a  decrease in the ejaculate.

In addition, in clinical studies and in post-marketing applications, breast cancer has been reported in men taking finasteride. You should immediately inform your doctor about any changes in the tissues of the mammary gland, namely, swelling, pain, gynecomastia or discharge from the nipples.

The MTOPS study compared finasteride, 5 mg / day (n = 768), doxazosin, 4 or 8 mg / day (n = 756), combination therapy with finasteride, 5 mg / day, and doxazosin, 4 or 8 mg / day (n = 786), and placebo (n = 737). The safety and tolerability profile of combination therapy corresponded to the profiles of the individual components. The incidence of ejaculatory disorders in patients taking combination therapy was the comparative sum of the incidence of adverse reactions for the two monotherapy.

In a seven-year, placebo-controlled study involving 18882 healthy men, of which 9060 needle prostate biopsy data were available for analysis, prostate cancer was detected in 803 (18.4%) men taking Proscar  ® and in 1147 (24.4%) men who took a placebo. In the administration group of the drug Proscar  ®  280, men (6.4%) had prostate cancer with Gleason scores of 7-10 detected by needle biopsy, compared with 237 (5.1%) men in the placebo group. Additional tests indicate that the increased benefits of high-grade prostate cancer that were observed in the Proscar ® administration group can be explained by the influence of Proscar  ®  on the volume of the prostate. Of the total cases of prostate cancer diagnosed in this study, 98% of cases were classified as Intracapsular (stage T1 or T2) cancer. Information on the relationship between prolonged use of Proscar's and tumors with a Gleason score of 7-10 is not available.

Laboratory Analysis Data

When evaluating laboratory studies of prostate-specific antigen (PSA), it should be borne in mind that PSA levels are reduced in patients taking Proscar. In most patients, a rapid decrease in PSA is observed in the first months of therapy, after which the PSA level stabilizes to a new initial level. The initial level after treatment is approximately half the value before treatment. Therefore, in most patients taking Proscar for six months or more, PSA values ​​should be doubled to compare with normal ranges in men, not treated.

In standard laboratory tests, there were no other differences between patients receiving Proscar and patients receiving a placebo. 


In patients who received Proscar in a dose of up to 400 mg once and Proscar in a dose of up to 80 mg per day for 3 months, any unwanted effects were absent.

There are no specific treatment recommendations for an overdose of Proscar.


No clinically significant interactions with other drugs have been identified. Proscar does not have a noticeable effect on the enzyme system, which is metabolized by drugs associated with cytochrome P450. Although the risk that finasteride affects the pharmacokinetics of other drugs is assessed to be small, it is likely that inhibitors and inducers of cytochrome P450 3A4 affect plasma concentrations of finasteride. However, given the established safety indicators, any increase in finasteride concentration due to the simultaneous use of cytochrome P450 3A4 inhibitors is unlikely to have clinical significance. Human-tested compounds include propranolol, digoxin, glyburide, warfarin, theophylline, and antipyrine; no clinically significant interactions were found.